Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PROVE A Randomized Phase II Trial of Standard Carboplatin and Pegylated Liposomal Doxorubicin With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

Next Previous
Trial Profile

PROVE A Randomized Phase II Trial of Standard Carboplatin and Pegylated Liposomal Doxorubicin With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panitumumab (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms PROVE
  • Sponsors Wissenschaftlicher Service Pharma

    • Most Recent Events

    • 06 Jun 2017 Primary endpoint (Progression-free survival (PFS) rate after 12 months.) has not been met, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top